EU‑GMP path in motion
Premium, science backed medical cannabis grown in Greece.
EU‐GMP path in motion. Owned land. Fully planned facility. First harvest targeted March 2027.
EU‐GMP path in motion. Owned land. Fully planned facility. First harvest targeted March 2027.
From ownership to operations, every step is transparent, certified, and science-led.
EU-GMP / GACP strategy locked; timeline public and auditable.
R&D with University of Athens & University of Hohenheim; batch-release via CoAs.
Detailed cost lines; general contractor scope; investor protections built in.
Ownership, design, and funding transparency — verified, documented, and ready for audit.
Ownership verified; Gazette license framework covers > 0.2% THC (medical) & export (specs TBC).
60-day cycle · 5 harvests / year · controlled flows for compliance.
CapEx USD 5.17 M (78%) · 6-month OpEx USD 1.34 M (20%) · Consulting USD 0.15 M (2%) .
We believe that credibility comes from clarity — not from promises. That’s why we publish the facts exactly as they are: what’s ready, what’s in motion, and what’s still ahead.
From land acquisition to GMP-certified production, every step is planned, tracked, and transparent.
Standard operating procedures setup
Mock audit & corrective actions
Full regulatory audit
Commercial production
Kenevir Medical is a vertically integrated medical cannabis company based in Greece, dedicated to delivering premium, science-backed products across Europe. We combine owned land, controlled cultivation, and GMP-ready processing to ensure the highest standards of quality, safety, and reproducibility.
Our operations are built on a foundation of transparency and regulatory compliance, with a clearly defined roadmap from cultivation to market. Partnering with the University of Athens and the University of Hohenheim, we continuously optimize genetics, post-harvest handling, and batch verification, with every lot validated through independent Certificates of Analysis (CoAs). With a targeted first harvest in March 2027 and EU-GMP certification by Summer 2027 , Kenevir provides a de-risked pathway for investors and partners seeking predictable, high-quality supply.
Governance structures, budget oversight, and advisory boards are integrated from day one, reinforcing accountability and investor confidence.
